Horizon Therapeutics plc Announces FDA Approval of an Update

-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced

Related Keywords

Ireland , United States , Tina Ventura , Rachel Vann , Tim Walbert , Linkedin , European Group On Grave Orbitopathy , Visa , Exchange Commission , Twitter , Drug Administration , Facebook , Product Communications , Nasdaq , European Group On Grave , Instagram , Thyroid Eye , Eye Disease , Thyroid Eye Disease , Inflammatory Bowel Disease , Full Prescribing Information , United States Securities , Thyroid Associated , Grave Disease Is Mediated Through , Insulin Like Growth Factor , European Group , Grave Orbitopathy , Vice President , Chief Investor Relations Officer , Horizon , Herapeutics , Nnounces , Approval , Update , Indication , Language , Tepezza , Teprotumumab , Brbw , Specify , Thyroid , Disease , Patients , Regardless , Activity , Uration ,